Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome

ClinicalTrials.gov ID: NCT00355641

Public ClinicalTrials.gov record NCT00355641. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 4:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients With Restless Legs Syndrome (RLS)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to assess the safety and tolerability of ropinirole XR in the long-term treatment (up to 52 weeks)of adults with RLS.

Study identification

NCT ID
NCT00355641
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
450 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2005
Primary completion
Sep 30, 2007
Completion
Sep 30, 2007
Last update posted
Oct 27, 2016

2005 – 2007

United States locations

U.S. sites
59
U.S. states
24
U.S. cities
57
Facility City State ZIP Site status
GSK Investigational Site Alabaster Alabama 35007
GSK Investigational Site Jasper Alabama 35501
GSK Investigational Site Mesa Arizona 85201
GSK Investigational Site Phoenix Arizona 85050
GSK Investigational Site Sun City Arizona 85351
GSK Investigational Site Laguna Hills California 82653
GSK Investigational Site Northridge California 91325
GSK Investigational Site Oxnard California 93030
GSK Investigational Site Pasadena California 91106
GSK Investigational Site Redondo Beach California 90277
GSK Investigational Site Reseda California 91355
GSK Investigational Site San Diego California 92103
GSK Investigational Site Santa Monica California 90404
GSK Investigational Site Colorado Springs Colorado 80909
GSK Investigational Site Denver Colorado 80212
GSK Investigational Site Wheat Ridge Colorado 80033
GSK Investigational Site Boca Raton Florida 33486
GSK Investigational Site Largo Florida 33773
GSK Investigational Site St. Petersburg Florida 33701
GSK Investigational Site Stuart Florida 34996
GSK Investigational Site Tampa Florida 33609
GSK Investigational Site Atlanta Georgia 30338
GSK Investigational Site Atlanta Georgia 30342
GSK Investigational Site Austell Georgia 30106
GSK Investigational Site Dawsonville Georgia 30534
GSK Investigational Site Macon Georgia 31201
GSK Investigational Site Woodstock Georgia 30189
GSK Investigational Site Oak Brook Illinois 60523
GSK Investigational Site Lenexa Kansas 66214
GSK Investigational Site Topeka Kansas 66606
GSK Investigational Site Baton Rouge Louisiana 70808
GSK Investigational Site Springfield Massachusetts 01104
GSK Investigational Site Bingham Farms Michigan 48025
GSK Investigational Site Las Vegas Nevada 89119
GSK Investigational Site Cherry Hill New Jersey 08003
GSK Investigational Site Toms River New Jersey 08755
GSK Investigational Site Endwell New York 13760
GSK Investigational Site New York New York 10021
GSK Investigational Site Schenectady New York 12308
GSK Investigational Site Greenville North Carolina 27834
GSK Investigational Site Raleigh North Carolina 27607
GSK Investigational Site Cleveland Ohio 44130
GSK Investigational Site Columbus Ohio 43232
GSK Investigational Site Oklahoma City Oklahoma 73112
GSK Investigational Site Medford Oregon 97504-8456
GSK Investigational Site Portland Oregon 97210
GSK Investigational Site Columbia South Carolina 29201
GSK Investigational Site Mt. Pleasant South Carolina 29464
GSK Investigational Site Jackson Tennessee 38305
GSK Investigational Site Dallas Texas 75231
GSK Investigational Site San Antonio Texas 78229
GSK Investigational Site Salt Lake City Utah 84107
GSK Investigational Site Salt Lake City Utah 84121
GSK Investigational Site Alexandria Virginia 22311
GSK Investigational Site Charlottesville Virginia 22911
GSK Investigational Site Spokane Washington 99204
GSK Investigational Site Tacoma Washington 98405
GSK Investigational Site Walla Walla Washington 99362
GSK Investigational Site Wenatchee Washington 98801

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00355641, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 27, 2016 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00355641 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →